SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

BrainsWay Ltd. BRSYF OTC

Other OTC • Healthcare • Medical - Devices • IL • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

BrainsWay Ltd. (BRSYF) is a Medical - Devices company in the Healthcare sector, currently trading at $13.55. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Financials: revenue is $57M, +27.9%/yr average growth. Net income is $8M, growing at +140.3%/yr. Net profit margin is 14.6% (healthy). Gross margin is 75.4% (+1.6 pp trend).

Balance sheet: total debt is $7M against $73M equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 3.83 (strong liquidity). Debt-to-assets is 6%. Total assets: $113M.

Analyst outlook: 4 / 4 analysts rate BRSYF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 100/100 (Pass), Past 50/100 (Partial), Health 67/100 (Partial), Moat 52/100 (Partial), Future 100/100 (Pass), Income 55/100 (Partial).

BRSYF SharesGrow Score Overview

63/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 50/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 52/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BRSYF

BRSYF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BRSYF: +27.9%/yr revenue is, +140.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BRSYF: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BRSYF: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 3.83 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BRSYF: Gross margin is 75.4% (+1.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.

View details →

Analyst outlook: 4 / 4 analysts rate BRSYF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BRSYF: Net profit margin is 14.6%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range3.26-11.87

Volume300

Avg Volume (30D)10

Market Cap$542.45M

Beta (1Y)1.46

Share Statistics

EPS (TTM)0.22

Shares Outstanding$38.17M

IPO Date2011-04-21

Employees120

CEOHadar Levy

Financial Highlights & Ratios

Revenue (TTM)$56.53M

Gross Profit$42.63M

EBITDA$6.34M

Net Income$8.26M

Operating Income$4.68M

Total Cash$67.97M

Total Debt$6.82M

Net Debt$-61.15M

Total Assets$112.94M

Price / Earnings (P/E)61.6

Price / Sales (P/S)9.6

Analyst Forecast

Rating ConsensusBuy

Analysts Covering4

Buy 100% Hold 0% Sell 0%

Company Info

CountryIL

ExchangeOther OTC

CurrencyUSD

ISINIL0011007189

Price Chart

BRSYF

BrainsWay Ltd. ↗ · Other OTC

Healthcare • Medical - Devices

3.26 52WK RANGE 11.87

People Also View

IRadimed Corporation

Surmodics, Inc.

Varex Imaging Corporation

Sight Sciences, Inc.

Apyx Medical Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message